Jasper Therapeutics Analyst Ratings
Jasper Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 187.77% | Credit Suisse | → $4 | Reiterates | Outperform → Outperform |
| 08/11/2023 | 403.6% | Capital One | → $7 | Initiates Coverage On | → Overweight |
| 06/12/2023 | 392.81% | EF Hutton | → $6.85 | Reiterates | Buy → Buy |
| 05/25/2023 | 392.81% | EF Hutton | → $6.85 | Assumes | → Buy |
| 05/16/2023 | 475.54% | Oppenheimer | → $8 | Reinstates | Outperform → Outperform |
| 05/15/2023 | 392.81% | EF Hutton | → $6.85 | Reiterates | Buy → Buy |
| 05/15/2023 | 187.77% | Credit Suisse | → $4 | Reiterates | Outperform → Outperform |
| 03/09/2023 | 392.81% | EF Hutton | → $6.85 | Reiterates | → Buy |
| 03/09/2023 | 331.65% | Cantor Fitzgerald | → $6 | Reiterates | → Overweight |
| 03/09/2023 | 187.77% | Credit Suisse | → $4 | Reiterates | → Outperform |
| 02/27/2023 | 392.81% | EF Hutton | → $6.85 | Reiterates | → Buy |
| 02/21/2023 | 392.81% | EF Hutton | → $6.85 | Reiterates | → Buy |
| 02/17/2023 | 392.81% | EF Hutton | → $6.85 | Reiterates | → Buy |
| 02/16/2023 | 392.81% | EF Hutton | $4 → $6.85 | Maintains | Buy |
| 02/07/2023 | 331.65% | Cantor Fitzgerald | $10 → $6 | Reiterates | → Overweight |
| 01/11/2023 | 115.83% | Credit Suisse | $7 → $3 | Maintains | Outperform |
| 01/11/2023 | 187.77% | EF Hutton | → $4 | Maintains | Buy |
| 11/14/2022 | 475.54% | Oppenheimer | $21 → $8 | Maintains | Outperform |
| 11/01/2022 | 187.77% | EF Hutton | → $4 | Initiates Coverage On | → Buy |
| 07/13/2022 | 475.54% | Credit Suisse | $9 → $8 | Maintains | Outperform |
| 05/13/2022 | 547.48% | Credit Suisse | $10 → $9 | Maintains | Outperform |
| 02/28/2022 | 619.42% | Cantor Fitzgerald | → $10 | Initiates Coverage On | → Overweight |
| 02/25/2022 | 619.42% | Credit Suisse | $15 → $10 | Maintains | Outperform |
| 11/08/2021 | 979.14% | Credit Suisse | → $15 | Initiates Coverage On | → Outperform |
| 10/21/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 10/20/2021 | 1266.91% | BMO Capital | → $19 | Initiates Coverage On | → Outperform |
| 10/13/2021 | 1410.79% | Oppenheimer | → $21 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月14日 | 187.77% | 瑞士信贷 | →$4 | 重申 | 跑赢→跑赢大盘 |
| 2023年08月11日 | 403.6% | 大写一 | →$7 | 开始承保 | →超重 |
| 2023/06/12 | 392.81% | EF Hutton | →$6.85 | 重申 | 购买→购买 |
| 2023年05月25日 | 392.81% | EF Hutton | →$6.85 | 假设 | →购买 |
| 2023年05月16日 | 475.54% | 奥本海默 | →$8 | 恢复 | 跑赢→跑赢大盘 |
| 2023年05月15日 | 392.81% | EF Hutton | →$6.85 | 重申 | 购买→购买 |
| 2023年05月15日 | 187.77% | 瑞士信贷 | →$4 | 重申 | 跑赢→跑赢大盘 |
| 03/09/2023 | 392.81% | EF Hutton | →$6.85 | 重申 | →购买 |
| 03/09/2023 | 331.65% | 康托·菲茨杰拉德 | →$6 | 重申 | →超重 |
| 03/09/2023 | 187.77% | 瑞士信贷 | →$4 | 重申 | →跑赢大盘 |
| 02/27/2023 | 392.81% | EF Hutton | →$6.85 | 重申 | →购买 |
| 02/21/2023 | 392.81% | EF Hutton | →$6.85 | 重申 | →购买 |
| 02/17/2023 | 392.81% | EF Hutton | →$6.85 | 重申 | →购买 |
| 02/16/2023 | 392.81% | EF Hutton | $4→$6.85 | 维护 | 买 |
| 02/07/2023 | 331.65% | 康托·菲茨杰拉德 | $10→$6 | 重申 | →超重 |
| 2023年1月11日 | 115.83% | 瑞士信贷 | $7→$3 | 维护 | 跑赢大盘 |
| 2023年1月11日 | 187.77% | EF Hutton | →$4 | 维护 | 买 |
| 2022年11月14日 | 475.54% | 奥本海默 | $21→$8 | 维护 | 跑赢大盘 |
| 11/01/2022 | 187.77% | EF Hutton | →$4 | 开始承保 | →购买 |
| 07/13/2022 | 475.54% | 瑞士信贷 | $9→$8 | 维护 | 跑赢大盘 |
| 2022年05月13日 | 547.48% | 瑞士信贷 | $10→$9 | 维护 | 跑赢大盘 |
| 02/28/2022 | 619.42% | 康托·菲茨杰拉德 | →$10 | 开始承保 | →超重 |
| 02/25/2022 | 619.42% | 瑞士信贷 | $15→$10 | 维护 | 跑赢大盘 |
| 11/08/2021 | 979.14% | 瑞士信贷 | →$15 | 开始承保 | →跑赢大盘 |
| 2021/10/21 | - | 威廉·布莱尔 | 开始承保 | →跑赢大盘 | |
| 10/20/2021 | 1266.91% | 蒙特利尔银行资本 | →$19 | 开始承保 | →跑赢大盘 |
| 10/13/2021 | 1410.79% | 奥本海默 | →$21 | 开始承保 | →跑赢大盘 |
What is the target price for Jasper Therapeutics (JSPR)?
Jasper Treeutics(JSPR)的目标价格是多少？
The latest price target for Jasper Therapeutics (NASDAQ: JSPR) was reported by Credit Suisse on August 14, 2023. The analyst firm set a price target for $4.00 expecting JSPR to rise to within 12 months (a possible 187.77% upside). 19 analyst firms have reported ratings in the last year.
瑞士信贷于2023年8月14日报告了贾斯珀治疗公司(纳斯达克：JSPR)的最新目标价。这家分析公司将目标价定为4美元，预计JSPR将在12个月内上涨至(可能上涨187.77%)。去年有19家分析公司公布了评级。
What is the most recent analyst rating for Jasper Therapeutics (JSPR)?
贾斯珀治疗公司(JSPR)的最新分析师评级是什么？
The latest analyst rating for Jasper Therapeutics (NASDAQ: JSPR) was provided by Credit Suisse, and Jasper Therapeutics reiterated their outperform rating.
嘉士伯治疗公司(纳斯达克代码：JSPR)的最新分析师评级由瑞士信贷提供，嘉士伯治疗公司重申其表现优于大盘的评级。
When is the next analyst rating going to be posted or updated for Jasper Therapeutics (JSPR)?
Jasper治疗公司(JSPR)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Jasper Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Jasper Therapeutics was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Jasper Treeutics的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Jasper治疗公司的上一次评级是在2023年8月14日提交的，所以你应该预计下一次评级将在2024年8月14日左右提供。
Is the Analyst Rating Jasper Therapeutics (JSPR) correct?
分析师对Jasper Treeutics(JSPR)的评级正确吗？
While ratings are subjective and will change, the latest Jasper Therapeutics (JSPR) rating was a reiterated with a price target of $0.00 to $4.00. The current price Jasper Therapeutics (JSPR) is trading at is $1.39, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Jasper治疗公司(JSPR)的评级被重申，目标价在0.00美元到4.00美元之间。贾斯珀治疗公司(JSPR)目前的交易价格为1.39美元，在分析师的预测范围内。